Oct 6, 2022
Merck and Ridgeback announced that molnupiravir has no efficacy in vaccinated adults.
Merck and Ridgeback announced two real-world evidence data of Lagevrio (molnupiravir), an investigational COVID-19 drug. The first study, PANORAMIC, was conducted in the UK in highly vaccinated adults, most people of age less than 65 years. The second study, Clalit, was conducted in Israel, with most adults older than 65 with chronic heart conditions.
In the PANORAMIC study, two arms were considered; Lagevrio plus standard of care compared with standard of care alone. The primary endpoint was a reduction in hospitalization or death; 0.8% of hospitalization or death was reported in both arms.
In the Clalit study, Lagevrio was associated with fewer hospitalizations and death in older adults; however, there was no difference in the younger adults (less than 65 years of age).
Jan 18, 2022
Merck and Ridgeback to supply 3 million courses of molnupiravir to UNICEF
Merck and Ridgeback Biotherapeutics announced that they had signed a long-term agreement to supply 3 million doses of molnupiravir to the United Nations Children’s Fund (UNICEF). These 3 million doses will be supplied to middle and lower-income countries.
Molnupiravir is approved in the US, Japan, and the UK for treating mild to moderate COVID19 infection.
Jan 11, 2022
GSK and Vir Biotechnology to supply 600,000 additional doses of sotrovimab to the US
GSK and Vir Biotechnology announced that they have agreed to supply an additional 600,000 doses of sotrovimab to the US government to access the drug across the nation further. GSK and Vir Biotechnology have agreed to provide 1.7 million doses of sotrovimab globally.
Also read: WHO granted EUL to Covaxin; acclaims easy storage requirement
GSK announced that testing the drug in live viruses and pseudoviruses showed effectiveness against the Delta and Omicron variants.
Also read: Top 10 pharma companies by revenues in 2021
Sotrovimab has received emergency use authorization from the US FDA in May 2021. Under the EUA, it can be used for mild-to-moderate COVID19 patients who are at risk of progressing to severe disease.
Also read: Why the cost of prescription drugs is high in the US?